Evidence map›Paper›PMID 31032471›Full record

ArticleJCO precision oncology2017

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed

Meghan J Mooradian, Zofia Piotrowska, Benjamin J Drapkin, Dora Dias-Santagata, Nicolas Marcoux, Konstantinos Arnaoutakis, Rebecca J Nagy, Richard Lanman, Anthony J Iafrate, Anna F Farago and 3 more

Abstract read
In one paragraph

Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Influence ofJCO precision oncology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meghan J Mooradian *Massachusetts General Hospital, Boston, MA.
Zofia Piotrowska *Massachusetts General Hospital, Boston, MA.
Benjamin J DrapkinMassachusetts General Hospital, Boston, MA.
Dora Dias-SantagataMassachusetts General Hospital, Boston, MA.
Nicolas MarcouxMassachusetts General Hospital, Boston, MA.
Konstantinos ArnaoutakisUniversity of Arkansas for Medical Sciences, Little Rock, AR.
Rebecca J NagyGuardant Health, Redwood City, CA.
Richard LanmanGuardant Health, Redwood City, CA.
Anthony J IafrateMassachusetts General Hospital, Boston, MA.
Anna F FaragoMassachusetts General Hospital, Boston, MA.
Mari Mino-KenudsonMassachusetts General Hospital, Boston, MA.
Aaron N HataMassachusetts General Hospital, Boston, MA.
Lecia V SequistMassachusetts General Hospital, Boston, MA.

Funding

The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted TherapiesR01CA137008 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, ZOFIA PIOTROWSKA · 2009 to 2026
$5.7M
Evolution of resistance of EGFR mutant non-small cell lung cancerK08CA197389 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HATA, AARON N · 2016 to 2020
$896k
NCI NIH HHS K08 CA197389NCI NIH HHS R01 CA137008
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31032471
PMCPMC6483387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.